TO EVALUATE THE EFFECT OF INTRALESIONAL VIT D-3 INJECTION IN CUTANEOUS WARTS
DOI:
https://doi.org/10.22159/ijcpr.2026v18i2.8072Keywords:
Cutaneous warts, Human papillomavirus, Palmar warts, Plantar warts, Verruca plana, Treatment outcome, CryotherapyAbstract
Objective: To study the demographic characteristics, clinical types, and treatment response patterns of patients with cutaneous warts attending a dermatology outpatient department.
Methods: This was a descriptive observational study including patients diagnosed with cutaneous warts. Demographic details, clinical characteristics, including type, number, and duration of warts, and management outcomes were recorded. Treatment response was assessed based on clinical resolution following treatment sittings.
Results: The study population comprised 51% females and 49% males, with a mean age of 28.83±9.53 years. The most affected age group was 21–30 years (42%). Palmar warts were the most common clinical type (42%), followed by verruca plana (29%) and plantar warts (27%). The mean number of warts was 5.43±2.36, and the mean duration of disease was 6.45±3.25 mo. Most patients required four treatment sittings (67%). Complete response was observed in 48% of patients, while 21% showed partial response and 31% had no response to treatment.
Conclusion: Cutaneous warts predominantly affected young adults and presented with varied clinical morphology and lesion burden. Multiple treatment sittings were often required, with variable therapeutic responses. These findings highlight the chronic nature of cutaneous warts and the need for individualized management strategies.
Downloads
References
1. Tripathi A, Sahu U. An overview of HPV: causes, symptoms and clinical manifestations. In: Immunopathology diagnosis and treatment of HPV-induced malignancies. Amsterdam: Elsevier; 2022. p. 1-19. doi: 10.1016/B978-0-323-91797-1.00003-X.
2. Wolf J, Kist LF, Pereira SB, Quessada MA, Petek H, Pille A. Human papillomavirus infection: epidemiology, biology host interactions, cancer development, prevention and therapeutics. Rev Med Virol. 2024;34(3):e2537. doi: 10.1002/rmv.2537, PMID 38666757.
3. Abdullah HI, Hassan AH. Clinicoepidemiological findings and pathological characteristics of different types of cutaneous warts. KJAR. 2025 Jun 20;10(1):158-69. doi: 10.24017/science.2025.1.10.
4. Skubic L, Breznik V, Poljak M. Different skin wart types, different human papillomavirus types? a narrative review. Acta Dermatovenerol Alp Pannonica Adriat. 2023 Dec;32(4):165-71. doi: 10.15570/actaapa.2023.30, PMID 38126099.
5. Redzic N, Pereira AR, Menon S, Bogers J, Coppens A, Kehoe K. Characterization of type-specific HPV prevalence in a population of persistent cutaneous warts in Flanders Belgium. Sci Rep. 2023 Oct 15;13(1):17492. doi: 10.1038/s41598-023-44154-y, PMID 37840107.
6. Elsayed Ghaly N, El-Ashmawy AA, Abou Zeid M, E Shaker ES. Efficacy and safety of intralesional injection of vitamin D3 versus tuberculin PPD in the treatment of plantar warts: a comparative controlled study. J Cosmet Dermatol. 2021;20(4):1231-40. doi: 10.1111/jocd.13712, PMID 32892493.
7. Almuhyi RA, Alhamdi KI, Alhamdi DK. Topical vitamin D3 derivative (calcipotriol) versus intralesional vitamin D3 in the treatment of cutaneous warts: a clinical therapeutic comparative trial. Dermatol Res Pract. 2024;2024(1):5236290. doi: 10.1155/2024/5236290, PMID 39534647.
8. Witchey DJ, Witchey NB, Roth Kauffman MM, Kauffman MK. Plantar warts: epidemiology, pathophysiology and clinical management. J Am Osteopath Assoc. 2018 Feb 1;118(2):92-105. doi: 10.7556/jaoa.2018.024, PMID 29379975.
9. Magalhaes GM, Vieira EC, Garcia LC, De Carvalho Leite ML, Guedes AC, Araujo MG. Update on human papilloma virus part I: epidemiology pathogenesis and clinical spectrum. An Bras Dermatol. 2021;96(1):1-16. doi: 10.1016/j.abd.2020.11.003, PMID 33341319.
10. Karki S, Pradhan M, Rai A. Warts among patients visiting the outpatient department of dermatology in a tertiary care centre: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2022 Sep;60(253):770-3. doi: 10.31729/jnma.7544, PMID 36705137.
11. Liu J, Li H, Yang F, Ren Y, Xia T, Zhao Z. Epidemiology and clinical profile of cutaneous warts in Chinese college students: a cross-sectional and follow-up study. Sci Rep. 2018 Oct 18;8(1):15450. doi: 10.1038/s41598-018-33511-x, PMID 30337549.
12. Ghadgepatil SS, Gupta S, Sharma YK. Clinicoepidemiological study of different types of warts. Dermatol Res Pract. 2016;2016:7989817. doi: 10.1155/2016/7989817, PMID 27047542.
13. Jiravsky O, Spacek R, Chovancik J, Neuwirth R, Hudec M, Sknouril L. Early ganglion stellate blockade as part of a two-step treatment algorithm suppresses electrical storm and need for intubation. Hellenic J Cardiol. 2023 Sep 1;73:24-35. doi: 10.1016/j.hjc.2023.04.003, PMID 37088344.
14. Plastow R, Kerkhoffs GM, Wood D, Paton BM, Kayani B, Pollock N. London international consensus and delphi study on hamstring injuries part 2: operative management. Br J Sports Med. 2023 Mar;57(5):266-73. doi: 10.1136/bjsports-2022-106345.
15. Garcia C, Karri J, Zacharias NA, Abd-Elsayed A. Use of cryotherapy for managing chronic pain: an evidence-based narrative. Pain Ther. 2021 Jun 1;10(1):81-100. doi: 10.1007/s40122-020-00225-w, PMID 33315183.
16. Chaudhary D, Sun Y, Gao X. Comparison of cryotherapy and topical salicylic acid in common warts: a systematic review and meta-analysis. Dermatol Ther. 2023;2023(1):4283918. doi: 10.1155/2023/4283918.
17. Zhu P, Qi RQ, Yang Y, Huo W, Zhang Y, He L. Clinical guideline for the diagnosis and treatment of cutaneous warts (2022). J Evid Based Med. 2022;15(3):284-301. doi: 10.1111/jebm.12494, PMID 36117295.
18. Sandru F, Radu AM, Petca A, Dumitrascu MC, Petca RC, Roman AM. Unveiling the therapeutic horizon: HPV vaccines and their impact on cutaneous diseases-a comprehensive review. Vaccines. 2024 Feb 23;12(3):228. doi: 10.3390/vaccines12030228, PMID 38543862.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Vineet Singh, Mohammad Mudassir, Sushil Yadav
This work is licensed under a Creative Commons Attribution 4.0 International License.